ARKK
SRTA
Same story, different day
Cathie Wood’s Ark is back on the sell button. On April 13, ARK Investment Management unloaded 182,767 shares of Strata Critical Medical, worth about $738,378, across its ARKQ and ARKX ETFs.
Not exactly a love letter
This wasn’t some random portfolio sneeze, either. Ark has been trimming SRTA basically every day, including a sale of 75,389 shares on April 10. In other words, this looks less like “oops” and more like a deliberate reallocation.
What’s the play here?
Ark has a habit of sliding money around to where it thinks the future is juiciest — usually somewhere in the neighborhood of AI, fintech, or genomics. So if you own SRTA, the important question isn’t just “why sell?” It’s “what’s getting the capital instead?”
Meanwhile, Strata Critical Medical has been putting up its own solid numbers, with growth, profitability improvements, and even a raised 2026 guide. So this isn’t obviously a panic exit. It’s more like a fund manager saying, “Nice stock, but I’ve got another shiny object calling.”
Big picture: Ark’s persistent selling tells you where its conviction is cooling, even if the business itself is still chugging along.